Experimental confirmation of antimicrobial effects of GdYVO4:Eu3+ nanoparticles

Basit Öğe Kaydı
dc.authoridMaksimchuk, Pavel/0000-0001-5448-1274
dc.authoridTkachenko, Anton/0000-0002-1029-1636
dc.authoridYefimova, Svetlana/0000-0003-2092-1950
dc.contributor.authorGonca, Serpil
dc.contributor.authorOzdemir, Sadin
dc.contributor.authorYefimova, Svetlana
dc.contributor.authorTkachenko, Anton
dc.contributor.authorOnishchenko, Anatolii
dc.contributor.authorKlochkov, Vladimir
dc.contributor.authorKavok, Nataliya
dc.date.accessioned2025-03-17T12:25:47Z
dc.date.available2025-03-17T12:25:47Z
dc.date.issued2021
dc.departmentTarsus Üniversitesi
dc.description.abstractNanotechnology can be applied to design antibacterial agents to combat antibiotic resistance. The aim of the present study was to assess the antimicrobial effects and cytotoxicity of GdYVO4:Eu3+ nanoparticles (NPs). Biofilm inhibition activity, antimicrobial activity, bacterial viability inhibition and DNA cleavage activity of GdYVO4:Eu3+ NPs were studied. In addition, the impact of GdYVO4:Eu3+ NPs on the mitochondrial membrane potential (Delta psi(M)) of host immune cells and, hence, their apoptosis was analyzed by JC-1 staining using flow cytometry. GdYVO4:Eu3+ NPs demonstrated good antimicrobial, cell viability inhibition and DNA cleavage activities. In addition, GdYVO4:Eu3+ NPs showed good biofilm inhibition activity against S. aureus and P. aeruginosa and inhibition percentages were 89.15% and 79.54%, respectively. However, GdYVO4:Eu3+ NPs promoted mitochondrial depolarization and apoptosis of leukocytes at high concentrations. GdYVO4:Eu3+ nanoparticles are promising antibacterial agents. However, more efforts should be exerted to ensure their safety.
dc.description.sponsorshipMinistry of Health of Ukraine [0121U110920]
dc.description.sponsorshipThe research was funded by the Ministry of Health of Ukraine as a fragment of the project entitled `Research of Efficiency, Mechanisms of Action and Safety of Use of Orthovanadate Nanoparticles of Rare Earth Elements for Optimization of Radiation Therapy in the Conditions of Oncopathology' [state registration number 0121U110920].
dc.identifier.doi10.1080/03639045.2022.2075007
dc.identifier.endpage1974
dc.identifier.issn0363-9045
dc.identifier.issn1520-5762
dc.identifier.issue12
dc.identifier.pmid35514217
dc.identifier.scopus2-s2.0-85130448178
dc.identifier.scopusqualityQ1
dc.identifier.startpage1966
dc.identifier.urihttps://doi.org/10.1080/03639045.2022.2075007
dc.identifier.urihttps://hdl.handle.net/20.500.13099/1879
dc.identifier.volume47
dc.identifier.wosWOS:000795737500001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofDrug Development and Industrial Pharmacy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250316
dc.subjectJC-1
dc.subjectmitochondrial membrane potential
dc.subjectDNA cleavage
dc.subjectbiofilm inhibition activity
dc.subjectantimicrobial activity
dc.subjectbacterial viability
dc.subjectnanoparticles
dc.titleExperimental confirmation of antimicrobial effects of GdYVO4:Eu3+ nanoparticles
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu